Lupin announced its plan to use Honeywell’s (HON) Solstice Air propellant to transform respiratory care through the development of next-generation inhalers. Designed for patients with asthma and chronic obstructive pulmonary disease, Honeywell Solstice Air has the potential to prevent the release of high global warming potential molecules. Lupin intends to become the first pharmaceutical company in India to use Honeywell’s Solstice Air product at scale as a next-generation propellant in pressurized metered-dose inhalers. The terms of the deal are subject to negotiation and execution of definitive documents acceptable to both Honeywell and Lupin.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HON:
- The Quantum Revolution Is Closer Than You Think — Here’s What Investors Need to Know
- Honeywell price target raised to $250 from $235 at Mizuho
- Honeywell price target raised to $217 from $182 at JPMorgan
- Paulson buys Honeywell, boosts Madrigal in Q1
- ‘A Defining Moment in Qatar’s Ambitions’: $1B Deal with Quantinuum Puts Qatar on Tech Investing Map